Truist lowered the firm’s price target on Integra LifeSciences (IART) to $13 from $15 and keeps a Hold rating on the shares. The firm notes it was surprised to see a Q3 revenue miss following multiple rebased outlooks, including last quarter. The intra-quarter issues impacted the business and more than overshadowed progress made on profitability and free cash flow, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IART:
- Integra LifeSciences Earnings Call: Mixed Sentiment and Strategic Advancements
- Integra LifeSciences price target raised to $13 from $12 at JPMorgan
- Integra LifeSciences price target lowered to $11 from $12 at Citi
- Integra Lifesciences Faces Revenue Shortfall and Lowered Outlook Amid Supply Chain Challenges
- Integra LifeSciences Reports Strong Q3 2025 Results